U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Lymphocyte-Rich Classic Hodgkin Lymphoma

MedGen UID:
1634873
•Concept ID:
C4684941
•
Neoplastic Process
Synonym: Refractory Lymphocyte-Rich Classical Hodgkin Lymphoma

Definition

Lymphocyte-rich classic Hodgkin lymphoma that does not respond to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Lymphocyte-Rich Classic Hodgkin Lymphoma

Professional guidelines

PubMed

Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol 2022 Nov;97(11):1478-1488. Epub 2022 Sep 19 doi: 10.1002/ajh.26717. PMID: 36215668
Treatment strategies for patients with diffuse large B-cell lymphoma.
Poletto S, Novo M, Paruzzo L, Frascione PMM, Vitolo U
Cancer Treat Rev 2022 Nov;110:102443. Epub 2022 Jul 31 doi: 10.1016/j.ctrv.2022.102443. PMID: 35933930
Hodgkin Lymphoma: Diagnosis and Treatment.
Ansell SM
Mayo Clin Proc 2015 Nov;90(11):1574-83. doi: 10.1016/j.mayocp.2015.07.005. PMID: 26541251

Recent clinical studies

Etiology

Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol 2022 Nov;97(11):1478-1488. Epub 2022 Sep 19 doi: 10.1002/ajh.26717. PMID: 36215668
Pediatric Hodgkin Lymphoma, Version 3.2021.
Flerlage JE, Hiniker SM, Armenian S, Benya EC, Bobbey AJ, Chang V, Cooper S, Coulter DW, Cuglievan B, Hoppe BS, Isenalumhe L, Kelly K, Kersun L, Lamble AJ, Larrier NA, Magee J, Oduro K, Pacheco M, Price AP, Roberts KB, Smith CM, Sohani AR, Trovillion EM, Walling E, Xavier AC, Burns JL, Campbell M
J Natl Compr Canc Netw 2021 Jun 30;19(6):733-754. doi: 10.6004/jnccn.2021.0027. PMID: 34214968
Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol 2020 Aug;95(8):978-989. Epub 2020 Jun 8 doi: 10.1002/ajh.25856. PMID: 32384177
Hodgkin lymphoma: A review and update on recent progress.
Shanbhag S, Ambinder RF
CA Cancer J Clin 2018 Mar;68(2):116-132. Epub 2017 Dec 1 doi: 10.3322/caac.21438. PMID: 29194581Free PMC Article
Hodgkin Lymphoma: Diagnosis and Treatment.
Ansell SM
Mayo Clin Proc 2015 Nov;90(11):1574-83. doi: 10.1016/j.mayocp.2015.07.005. PMID: 26541251

Diagnosis

Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol 2022 Nov;97(11):1478-1488. Epub 2022 Sep 19 doi: 10.1002/ajh.26717. PMID: 36215668
Hodgkin lymphoma.
Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL
Nat Rev Dis Primers 2020 Jul 23;6(1):61. doi: 10.1038/s41572-020-0189-6. PMID: 32703953
Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol 2020 Aug;95(8):978-989. Epub 2020 Jun 8 doi: 10.1002/ajh.25856. PMID: 32384177
Hodgkin lymphoma: A review and update on recent progress.
Shanbhag S, Ambinder RF
CA Cancer J Clin 2018 Mar;68(2):116-132. Epub 2017 Dec 1 doi: 10.3322/caac.21438. PMID: 29194581Free PMC Article
Hodgkin Lymphoma: Diagnosis and Treatment.
Ansell SM
Mayo Clin Proc 2015 Nov;90(11):1574-83. doi: 10.1016/j.mayocp.2015.07.005. PMID: 26541251

Therapy

Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol 2022 Nov;97(11):1478-1488. Epub 2022 Sep 19 doi: 10.1002/ajh.26717. PMID: 36215668
Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.
Mei MG, Lee HJ, Palmer JM, Chen R, Tsai NC, Chen L, McBride K, Smith DL, Melgar I, Song JY, Bonjoc KJ, Armenian S, Nwangwu M, Lee PP, Zain J, Nikolaenko L, Popplewell L, Nademanee A, Chaudhry A, Rosen S, Kwak L, Forman SJ, Herrera AF
Blood 2022 Jun 23;139(25):3605-3616. doi: 10.1182/blood.2022015423. PMID: 35316328Free PMC Article
Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol 2020 Aug;95(8):978-989. Epub 2020 Jun 8 doi: 10.1002/ajh.25856. PMID: 32384177
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM
J Clin Oncol 2018 May 10;36(14):1428-1439. Epub 2018 Mar 27 doi: 10.1200/JCO.2017.76.0793. PMID: 29584546Free PMC Article
Hodgkin Lymphoma: Diagnosis and Treatment.
Ansell SM
Mayo Clin Proc 2015 Nov;90(11):1574-83. doi: 10.1016/j.mayocp.2015.07.005. PMID: 26541251

Prognosis

Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol 2022 Nov;97(11):1478-1488. Epub 2022 Sep 19 doi: 10.1002/ajh.26717. PMID: 36215668
Hodgkin lymphoma.
Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL
Nat Rev Dis Primers 2020 Jul 23;6(1):61. doi: 10.1038/s41572-020-0189-6. PMID: 32703953
Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management.
Ansell SM
Am J Hematol 2020 Aug;95(8):978-989. Epub 2020 Jun 8 doi: 10.1002/ajh.25856. PMID: 32384177
Hodgkin lymphoma: A review and update on recent progress.
Shanbhag S, Ambinder RF
CA Cancer J Clin 2018 Mar;68(2):116-132. Epub 2017 Dec 1 doi: 10.3322/caac.21438. PMID: 29194581Free PMC Article
Hodgkin Lymphoma: Diagnosis and Treatment.
Ansell SM
Mayo Clin Proc 2015 Nov;90(11):1574-83. doi: 10.1016/j.mayocp.2015.07.005. PMID: 26541251

Clinical prediction guides

Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial.
Bryan LJ, Casulo C, Allen PB, Smith SE, Savas H, Dillehay GL, Karmali R, Pro B, Kane KL, Bazzi LA, Chmiel JS, Palmer BA, Mehta J, Gordon LI, Winter JN
JAMA Oncol 2023 May 1;9(5):683-691. doi: 10.1001/jamaoncol.2022.7975. PMID: 36928527Free PMC Article
Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults.
Harker-Murray P, Mauz-Körholz C, Leblanc T, Mascarin M, Michel G, Cooper S, Beishuizen A, Leger KJ, Amoroso L, Buffardi S, Rigaud C, Hoppe BS, Lisano J, Francis S, Sacchi M, Cole PD, Drachtman RA, Kelly KM, Daw S
Blood 2023 Apr 27;141(17):2075-2084. doi: 10.1182/blood.2022017118. PMID: 36564047Free PMC Article
Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.
Mei MG, Lee HJ, Palmer JM, Chen R, Tsai NC, Chen L, McBride K, Smith DL, Melgar I, Song JY, Bonjoc KJ, Armenian S, Nwangwu M, Lee PP, Zain J, Nikolaenko L, Popplewell L, Nademanee A, Chaudhry A, Rosen S, Kwak L, Forman SJ, Herrera AF
Blood 2022 Jun 23;139(25):3605-3616. doi: 10.1182/blood.2022015423. PMID: 35316328Free PMC Article
Hodgkin lymphoma.
Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL
Nat Rev Dis Primers 2020 Jul 23;6(1):61. doi: 10.1038/s41572-020-0189-6. PMID: 32703953
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, Park SI, Gee AP, Eldridge PW, McKay KL, Mehta B, Cheng CJ, Buchanan FB, Grilley BJ, Morrison K, Brenner MK, Serody JS, Dotti G, Heslop HE, Savoldo B
J Clin Oncol 2020 Nov 10;38(32):3794-3804. Epub 2020 Jul 23 doi: 10.1200/JCO.20.01342. PMID: 32701411Free PMC Article

Recent systematic reviews

Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review.
Arabloo J, Azari S, Gorji HA, Rezapour A, Alipour V, Ehsanzadeh SJ
Eur J Clin Pharmacol 2023 Nov;79(11):1443-1452. Epub 2023 Sep 1 doi: 10.1007/s00228-023-03557-6. PMID: 37656182
Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies.
Sun C, Chen H, Wang Y, Zheng C
Hematology 2023 Dec;28(1):2181749. doi: 10.1080/16078454.2023.2181749. PMID: 36892260
Brentuximab vedotin in pretreated Hodgkin lymphoma patients: a systematic review and meta-analysis.
Dada R, Zekri J, Al Saadi R
Expert Opin Biol Ther 2016 Jun;16(6):739-45. Epub 2016 May 3 doi: 10.1080/14712598.2016.1180362. PMID: 27096887
Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.
Martino M, Festuccia M, Fedele R, Console G, Cimminiello M, Gavarotti P, Bruno B
Expert Opin Biol Ther 2016;16(3):347-64. Epub 2016 Feb 6 doi: 10.1517/14712598.2015.1130821. PMID: 26652934
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.
Bonthapally V, Wu E, Macalalad A, Yang H, Shonukan O, Liu Y, Chi A, Huebner D
Curr Med Res Opin 2015 May;31(5):993-1001. Epub 2015 Apr 9 doi: 10.1185/03007995.2015.1030378. PMID: 25772232

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...